Clinical profile and initial treatment of non-small cell lung cancer: a retrospective cohort study at the Uganda Cancer Institute

Kibudde, Solomon; Kirenga, Bruce; Nabwana, Martin; Okuku, Fred; Walusansa, Victoria; Orem, Jackson

doi:10.4314/ahs.v21i4.30

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can be attributed to late stage at presentation and poor performance status. Late presentation of cancer is observed in non-small cell lung cancer [ 17 ], breast cancer [ 18 ], cervical cancer [ 19 ], prostate cancer [ 20 ], and head and neck cancers [ 21 ] in Uganda. Moreover, 35% and 41% of people with cancer in Uganda delay treatment initiation and miss clinic appointments, respectively, due to lack of money for drugs, transportation and accommodation [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

HIV-related lung cancer in Uganda: a cohort study

Baluku

Bogere

Namiiro

et al. 2022

Infect Agents Cancer

Self Cite

View full text Add to dashboard Cite

Background There are few reports on lung cancer among people with HIV (PWH) in Sub-Saharan Africa. In this report, we describe a cohort of PWH and lung cancer at the Uganda Cancer Institute. Methods This retrospective cohort of PWH and lung cancer was managed at the Uganda Cancer Institute between 2008 and 2018. Sociodemographic and clinical data were abstracted from the patient charts. The median survival from diagnosis to death, loss-to-follow up or 31st December 2018, was estimated. Results There were 18 people with HIV and lung cancer. The median (interquartile range, IQR) age was 49.5 (38.8–56.0) years, 11 (61.1%) were women and 5 (27.8%) were smokers. Of the 18 PWH, 13 (72.2%) were on antiretroviral therapy and the median (IQR) CD4 count (n = 13) was 380 (243.5–595) cells per mm3. Difficulty in breathing (88.9%), chest pain (78.6%, n = 11), cough (76.5%, n = 17) and weight loss (72.2%) were the commonest symptoms while pleural effusions were observed in 12 (66.7%). In this cohort, 8 (44.4%) were presumptively treated for tuberculosis before the diagnosis of lung cancer. Seven (38.9%) had an Eastern Cooperative Oncology Group performance status of 3. Non-small cell lung cancer was the predominant histological type observed in 17 (94.4%) of whom 14 (82.4%) had adenocarcinoma. Majority of PWH had stage IV disease (88.9%). The median (IQR) survival was 3.3 (1.1–13.2) months and all were either dead (72.2%) or lost-to-follow up (27.8%) at five years from diagnosis. Conclusion People with HIV and lung cancer in Uganda report low rates of smoking, present with advanced disease and post very poor survival rates. There is need for biomarkers for early detection of lung cancer in HIV.

show abstract

Section: Discussionmentioning

confidence: 99%

HIV-related lung cancer in Uganda: a cohort study

Baluku

Bogere

Namiiro

et al. 2022

Infect Agents Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lung cancer has become the malignant tumor with the greatest threat to human health and life worldwide due to its higher incidence and mortality than other malignant tumors, accounting for 11.6% of cancer patients and 18.4% of total cancer deaths ( 37 , 38 ). Among all lung cancer patients, NSCLC accounts for approximately 80%-85% of the total population.…”

Section: Role and Mechanism Of Tmem88 In Malignant Tumorsmentioning

confidence: 99%

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Cai

Ni²,

Wang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

According to authoritative surveys, the overall morbidity and mortality of malignant tumors show an upward trend, and it is predicted that this trend will not be well contained in the upcoming new period. Since the influencing factors, pathogenesis, and progression characteristics of malignant tumors have not been fully elucidated, the existing treatment strategies, mainly including surgical resection, ablation therapy and chemotherapy, cannot achieve satisfactory results. Therefore, exploring potential therapeutic targets and clarifying their functions and mechanisms in continuous research and practice will provide new ideas and possibilities for the treatment of malignant tumors. Recently, a double-transmembrane protein named transmembrane protein 88 (TMEM88) was reported to regulate changes in downstream effectors by mediating different signaling pathways and was confirmed to be widely involved in cell proliferation, differentiation, apoptosis and tumor progression. At present, abnormal changes in TMEM88 have been found in breast cancer, ovarian cancer, lung cancer, thyroid cancer and other malignant tumors, which has also attracted the attention of tumor research and attempted to clarify its function and mechanism. However, due to the lack of systematic generalization, comprehensive and detailed research results have not been comprehensively summarized. In view of this, this article will describe in detail the changes in TMEM88 in the occurrence and development of malignant tumors, comprehensively summarize the corresponding molecular mechanisms, and explore the potential of targeting TMEM88 in the treatment of malignant tumors to provide valuable candidate targets and promising intervention strategies for the diagnosis and cure of malignant tumors.

show abstract

“…The majority of patients diagnosed with non-small cell lung cancer (NSCLC) are already in the middle to late stages of the disease (1). At present, NSCLC patients often receive intravenous chemotherapy drugs, which can promote the improvement of quality of life and physical condition within 6 months after radical surgery (2).…”

Section: Introductionmentioning

confidence: 99%

Cinobufotalin effect and mechanism on serum MMP-2, MMP-9, Beclin1, LC3-II in advanced NSCLC patients

Lei Yang,

Bihui Bai,

Hongyu Chen

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study was conducted to explore cinobufotalin's effects and related mechanisms on serum MMP-2, MMP-9, Beclin1, and LC3-II in advanced non-small-cell lung cancer (NSCLC) patients. For this purpose, 150 patients with advanced NSCLC in our hospital from Jan. 2020 to Feb. 2022 were chosen as participants in the research study. Using a random number table method, the 150 patients were divided evenly into two groups -a control group (C) and an observation group (O). Group C received conventional NP regimen chemotherapy, while Group O received cinobufotalin capsules based on the control group. The follow-up was conducted for 4 months, and the differences in serum MMP-2, MMP-9, Beclin1, LC3-II and chemotherapy resistance rates were compared. Results showed that There was no statistically significant difference in MMP-2, MMP-9, Beclin1, and LC3-II levels between the two before treatment (P>0.05); 4 months later, Group O's MMP-2, MMP-9, Beclin1, and LC3-II levels were lower than those before treatment and Group C during the same period, with a statistically significant difference (P<0.05); At 4 months after treatment, the clinical efficacy of Group O was better and its ORR was higher, with a statistically significant difference (P<0.05); Using Pearson correlation analysis, a weak positive correlation was identified between MMP-2, Beclin1, LC3-II, and chemotherapy resistance (r=0.167, 0.197, 0.273, P<0.05), a positive correlation between MMP-2 and MMP-9, Beclin1, LC3-II (r=0.592, 0.852, 0.665, P<0.01), a positive correlation between MMP-9 and Beclin1, LC3-II (r=0.552, 0.472, P<0.01), and a positive correlation between Beclin1 and LC3-II (r=0.647, P<0.01). It was concluded that cinobufotalin has an inhibitory effect on the serum MMP-2, MMP-9, Beclin1, and LC3-II levels in advanced NSCLC patients, which can promote clinical efficacy improvement and reduce the risk of chemotherapy resistance by downregulating MMP-2, Beclin1, and LC3-II levels.

show abstract

Clinical profile and initial treatment of non-small cell lung cancer: a retrospective cohort study at the Uganda Cancer Institute

Cited by 3 publications

References 14 publications

HIV-related lung cancer in Uganda: a cohort study

HIV-related lung cancer in Uganda: a cohort study

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Cinobufotalin effect and mechanism on serum MMP-2, MMP-9, Beclin1, LC3-II in advanced NSCLC patients

Contact Info

Product

Resources

About